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Abstract
Few inhibitors exist for CD38, a multifunctional enzyme catalyzing the formation and metabolism of the Ca2+-mobilizing
second messenger cyclic adenosine 59-diphosphoribose (cADPR). Synthetic, non-hydrolyzable ligands can facilitate
structure-based inhibitor design. Molecular docking was used to reproduce the crystallographic binding mode of cyclic
inosine 59-diphosphoribose (N1-cIDPR) with CD38, revealing an exploitable pocket and predicting the potential to introduce
an extra hydrogen bond interaction with Asp-155. The purine C-8 position of N1-cIDPR (IC50 276 mM) was extended with an
amino or diaminobutane group and the 8-modified compounds were evaluated against CD38-catalyzed cADPR hydrolysis.
Crystallography of an 8-amino N1-cIDPR:CD38 complex confirmed the predicted interaction with Asp-155, together with a
second H-bond from a realigned Glu-146, rationalizing the improved inhibition (IC50 56 mM). Crystallography of a complex
of cyclic ADP-carbocyclic ribose (cADPcR, IC50 129 mM) with CD38 illustrated that Glu-146 hydrogen bonds with the ligand
N6-amino group. Both 8-amino N1-cIDPR and cADPcR bind deep in the active site reaching the catalytic residue Glu-226,
and mimicking the likely location of cADPR during catalysis. Substantial overlap of the N1-cIDPR ‘‘northern’’ ribose
monophosphate and the cADPcR carbocyclic ribose monophosphate regions suggests that this area is crucial for inhibitor
design, leading to a new compound series of N1-inosine 59-monophosphates (N1-IMPs). These small fragments inhibit
hydrolysis of cADPR more efficiently than the parent cyclic compounds, with the best in the series demonstrating potent
inhibition (IC50 = 7.6 mM). The lower molecular weight and relative simplicity of these compounds compared to cADPR make
them attractive as a starting point for further inhibitor design.
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Introduction
Cyclic ADP-ribose (cADPR, Figure 1) [1] is a second messenger
that mobilizes intracellular Ca2+ in various types of cells including
sea urchin eggs, T-cells and pancreatic b-cells. In biological
systems, cADPR is synthesized enzymatically from nicotinamide
adenine 59-dinucleotide (NAD+) by the action of ADP-ribosyl
cyclases. cADPR is readily hydrolyzed at the unstable N1 link to
give ADP-ribose (ADPR) in both neutral aqueous solution and
under physiological conditions [2–4], thus rendering chemical
synthesis of non-hydrolyzable analogues attractive. In-depth
reviews dealing with the chemistry of cADPR and the cADPR/
Ca2+ signaling system have been published in recent years [5–11].
Human CD38 is a multifunctional protein that triggers
proliferation and differentiation. The enzyme shares extensive
sequence similarity with Aplysia californica ADP-ribosyl cyclase
(ADPRC). It is principally an NAD+ glycohydrolase (NADase) that
transforms NAD+ into ADPR (Figure 1), but CD38 is also able to
produce a small amount of cADPR (ADP-ribosyl cyclase activity)
and to hydrolyze cADPR into ADPR (cADPR hydrolase activity)
[12], [13]. Studies have revealed the importance of CD38 in a
range of diseases, e.g. CD38 is a marker of AIDS progression and a
negative prognostic marker of chronic lymphocytic leukemia.
Recently, CD38 has been shown to be critical for social behavior
in mice [14]. Therefore, there is interest in developing new
inhibitors of CD38 to provide structural clues for designing
potential drug candidates for the treatment of CD38-related
diseases. Thus far, only inhibitors of the NAD+ glycohydrolase
activity of CD38 have been investigated. To date the best ones are
mechanism-based covalent inhibitors, which bind to the active site
of CD38. They have mainly been derived from NAD+, such as the
nicotinamide ribose derivatives reported by Schramm et al. which
exhibit Ki values in the nanomolar range [15], [16]. Zhang et al.
recently developed metabolically stable nicotinamide-based ana-
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logues which block endogenous CD38 activity in cells and tissues
[17]. Lee et al. published a study on membrane permeable
analogues, based on the nicotinamide motif, which are moderate
(low mM) inhibitors of the enzymatic activities of CD38 and
demonstrated their ability to relax agonist-induced muscle
contraction [18]. Wall et al. reported a non-hydrolyzable NAD+
analogue as a competitive inhibitor of CD38, with an IC50 of
about 100 mM [19]. Recently, other groups have successfully
explored and reported non-nucleotide compounds as inhibitors of
CD38. Kellenberger et al. showed that low micromolar concen-
trations of flavonoids inhibit CD38 [20]. Lately, Zhang and co-
workers obtained a hit compound from commercially available
libraries with an IC50 of 86 mM. Subsequent structural modifica-
tion led to the most active non-covalent inhibitor of CD38
NADase activity thus far with an IC50 of 4.7 mM [21].
The crystallographic structure of the catalytic domain of CD38
as well as the mechanism of catalysis by which cADPR is
metabolized have recently been elucidated using covalent inhib-
itors [22], [23]. Residue Glu-146 was identified as critical in
regulating the multi-functionality of CD38-mediated NAD+
hydrolysis, ADP-ribosyl cyclase and cADPR hydrolysis activities
[22], [24]. Glu-226 was identified as the catalytic residue as its
mutation essentially eliminates catalytic activity [25]. cADPR
forms two hydrogen bonds through N6 and N7 to Glu-146 and one
hydrogen bond with Asp-155 through N6. Lately, Liu et al. have
presented a comprehensive structural comparison study of CD38
and ADPRC [26]. Residue Phe-174 in ADPRC was identified as
crucial in directing the folding of the linear substrate for cyclisation
to occur. The equivalent residue Thr-221 in CD38 disfavors the
folding process required for cyclization, resulting in the observed
dominant NADase activity for this cyclase [26].
Soaking of CD38 crystals with cADPR itself led to rapid
hydrolysis of the ligand. Therefore, the crystal structure of cADPR
was solved in complex with an inactive mutant of CD38 in which
the catalytic residue Glu-226 had been mutated to Gln-226
(E226Q). In this catalytically inactive mutant, Gln-226 is not able
to fulfill the usual role of Glu-226, in interacting with the
‘‘northern’’ ribose (for nomenclature of compounds see Figure 2).
The crystal structure obtained with the E226Q mutant suggested
that cADPR bound ‘less deeply’ in the active site, yet cADPR must
be in close proximity to Glu-226 in the wild-type CD38 in order
for catalysis to occur [27].
To explore the CD38:cADPR interaction, we previously
designed a hydrolysis resistant cADPR analogue, cyclic inosine
59-diphosphoribose (N1-cIDPR, Figure 2), [28], [29] that was co-
crystallized with wild-type CD38. N1-cIDPR is a close structural
analogue of cADPR in which an oxo group at position 6 replaces
the amino group. It inhibits CD38-catalyzed cADPR hydrolysis
with an IC50 of 276 mM. In Jurkat T-cells, Ca2+ release induced by
N1-cIDPR is almost indistinguishable from Ca2+ release induced
by cADPR [29]. A crystal structure of N1-cIDPR with wild-type
CD38 [30] showed that N1-cIDPR binds in the active site, close to
the catalytic residue Glu-226 and that the two hydroxyl groups of
the ‘‘northern’’ ribose form two hydrogen bonds with this residue.
In contrast to cADPR, the O6 atom of N1-cIDPR does not favor a
hydrogen bond with Glu-146. This study has led to the most
complete elucidation of the pathway of cADPR hydrolysis by
CD38 yet and also facilitates, in principle, the possibility of
structure-based design of novel inhibitors of CD38 using the N1-
cIDPR template. We describe here the first successful steps on this
route. We report X-ray crystal structures of two non-hydrolyzable
inhibitors in complex with wild-type CD38, one using an 8-
substituted N1-cIDPR analogue derived from structure-based
design considerations and another using a different hydrolysis
resistant ligand, cADP carbocyclic ribose (cADPcR, Figure 2). We
also report the comparison of these crystal structures, which
suggests the design of simple, novel fragments that could maintain
key interactions with wild-type CD38. We describe the prepara-
Figure 1. Conversion of NAD+ into cADPR and ADPR.
doi:10.1371/journal.pone.0066247.g001
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tion of these compounds and their ability to inhibit cADPR
hydrolysis.
Experimental Procedures
General
All reagents and solvents were of highest commercial quality
and were used without further purification, unless described
otherwise. H2O was of MilliQ quality.
1H, 13C, and 31P NMR
spectra of final compounds were collected in D2O, either on a
JEOL Delta machine at 270 MHz (1H) or 109 MHz (31P), or on a
Varian Mercury system at 400 MHz (1H), 161 MHz (31P) or
100 MHz (13C). Chemical shifts (d) are reported in parts per
million (ppm). Abbreviations for splitting patterns are as follows:
br, broad; s, singlet; d, doublet; t, triplet; m, multiplet. UV spectra
were collected in aqueous solution on a Perkin Elmer Lambda EZ
201 or Lambda 3B spectrophotometer. HPLC analysis was carried
out on a Waters 2695 Alliance module equipped with a Waters
2996 Photodiode Array Detector (210–350 nm). The chromato-
graphic system consisted of a Hichrom Guard Column for HPLC
and a Phenomenex Synergi 4u MAX-RP 80A column
(15064.60 mm), eluted at 1 mL/min with the following ion-pair
buffer: 0.17% (m/v) cetrimide and 45% (v/v) phosphate buffer
(pH 6.4) in MeOH. Preparative chromatography was performed
on a Pharmacia Biotech Gradifrac system equipped with a
peristaltic P-1 Pump and a fixed wavelength UV-1 Optical Unit
(280 nm). Synthetic phosphates were assayed by an adaptation of
the Briggs phosphate test [31].
Molecular Modeling: cIDPR Analogues
Crystal structures of N1-cIDPR complexed with wild-type
CD38 were obtained from the Protein Data Bank (PDB codes
2PGJ and 2PGL) [30]. Chain B was deleted from the crystal
structure, as were all water molecules at a distance greater than 5A˚
from the ligand associated with chain A. Hydrogens were built
onto the whole structure. All atoms with the exception of
hydrogens were fixed in SYBYL aggregates, and hydrogens were
energy minimized until convergence using the TRIPOS F.F force
field with Gasteiger-Hu¨ckel charges applied. The docking
calculations for N1-cIDPR and analogues were performed with
the GOLD molecular docking package (version 3.0.1) [32–35].
The active site was defined as a 15A˚ sphere around the Thr-221
side chain oxygen atom and 50 attempts were computed for each
inhibitor. From 50 docking attempts, one cluster was produced
which mimicked the binding mode in the crystal structure. The
ligand was energy minimized with the aromatic system in
aggregates.
Figure 2. Structure and nomenclature of cADPR and analogues used in this study. The ‘‘northern’’ and ‘‘southern’’ riboses of the cyclic
analogues are distinguished by adopting prime (9) and double prime (0) notation respectively for their sugar carbons.
doi:10.1371/journal.pone.0066247.g002
CD38 Structure-Based Inhibitor Design
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e66247
N1-IMP Analogues
The 2PGJ and 3U4H crystal structures of human CD38 with
cIDPR and 8-amino cIDPR, respectively, were passed through the
Protein Preparation Wizard of the Schro¨dinger software running
under Maestro version 9.3.026: the incorrect planar ribose in the
2PGJ structure was manually corrected so that the ribose had the
appropriate structure and stereochemistry. Four cIDPR frag-
ments, where the cIDPR ‘‘southern’’ ribose phosphate is deleted,
were built in the Schro¨dinger software. The four compounds
differed in the substituent at the 8-position: hydrogen, bromine,
iodine or an amino group. The compounds were docked into the
prepared structure using GOLD version 5.1. The binding site was
defined as a sphere of 5A˚ radius centered on the centroid of the
ligand in the prepared structure: the centroid of the docked ligand
has to lie within this sphere. Each ligand was docked twenty-five
times. Selected poses were merged with the protein into which
they had been docked and the resulting complexes (with waters
present) were put through 1,000 rounds of energy minimization
using the Schro¨dinger software.
The ligand in the prepared 2PGJ and 3U4H crystal structures
was modified so that the ‘‘southern’’ ribose phosphate was deleted.
An amino group was added to the 8-position of the 2PGJ ligand.
The resulting complexes were put through 1,000 rounds of
minimization using the Schro¨dinger software. All figures were
prepared using PyMOL.
In our experience the water molecules in the CD38 substrate
binding site are very important when docking ligands. Without the
water molecules present we find that GOLD is unable to
reproduce the observed crystal structure poses and when docking
ligands for which no crystal structure pose is available for
comparison, docked poses obtained without water molecules
present are highly variable and generally cannot explain the
observed assay results.
Chemistry
cIDPR analogues. 8-amino N1-cIDPR [29], [36] and 8-
bromo N1-cIDPR [28] were synthesized by a chemo-enzymatic
procedure as previously described. cADPcR was prepared by total
chemical synthesis as described [37]. Synthesis of 8-(4-aminobu-
tane)amino N1-cIDPR was from 8-bromo N1-cIDPR using two
methods as follows: Method 1: To a solution of diaminobutane
(25 mL, 248 mmol) in MilliQ water (400 mL) was added 8-bromo
N1-cIDPR (5 mmol). The reaction mixture was left standing for 10
days after which it was neutralized with 6N HCl. The reaction was
diluted with MilliQ water to bring the conductivity down below
400 mS/cm and loaded onto an AG MP-1 ion exchange
chromatography, eluting products with a linear gradient of
150 mM TFA at 3 mL/min. The appropriate fractions were
collected and evaporated to dryness to afford the desired cyclic
dinucleotide (2.59 mmol, 52%) as a glassy solid. 1H (400 MHz,
D2O) d 8.77 (s, 1H, H-2), 5.93 (br s, 1H, H-10), 5.81 (d,
J19,29= 5.2 Hz, 1H, H-19), 5.26 (app. t, J29,19= J29,39= 5.2 Hz, 1H,
H-29), 4.64 (app.t, J= 4.3 Hz, 1H, H-39), 4.33–4.29 (m, 5H, H-
59a, H-50a, H-20, H-30 and H-40), 4.22–4.21 (m, 1H, H-49), 4.07
(dd, J50b,50a = 11.7 and J50b,40= 3.9 Hz, 1H, H-50b), 3.97–3.94 (m,
1H, H-59b), 3.43–3.42 (m, 2H, CH2), 2.94–2.92 (m, 2H, CH2) and
1.68–1.67 (m, 4H, 26CH2).
31P (109 MHz, D2O) d –10.5 (br s)
211.2 (br s). HRMS (ES+) calcd for C19H31N6O14P2 629.1368
(MH+) found 629.1357. UV (H2O) lmax 265 nm (e 13000). Method
2: A sealed flask containing a solution of diaminobutane (25 mL,
248 mmol) and 8-bromo N1-cIDPR (5 mmol) in MilliQ water
(400 mL) was incubated at 70uC in a microwave for 1 h after
which HPLC analysis showed total conversion of the starting
material to a single product. The mixture was neutralized and
product was purified as described in Method 1 to obtain the
desired product in quantitative yield.
N1-Inosine 59-Monophosphate Analogues
8-Bromo N1-IMP. 8-Bromo N1-IMP was prepared as
previously described [38].
8-Iodo N1-IMP. A solution of 8-iodo N1-cIDPR [36]
(5 mmol) in 0.2 M HCl (pH 1) was stirred at 60uC. After 24
hours, HPLC analysis showed completion of the reaction with the
appearance of a new peak at 10.2 mins (Rt (8-I-cIDPR) = 11.3 mins).
The reaction mixture was cooled to room temperature, neutral-
ized by addition of 2 M NaOH and product purified on a reverse-
phase column eluted with a gradient of MeCN in 0.05 M TEAB.
The appropriate fractions were collected, evaporated and treated
with chelex 100 to yield 8-iodo N1-IMP as a sodium salt (3.1 mmol,
62%) which showed 1H (400 MHz, D2O) d 8.46 (s, 1H, H-2), 6.23
(d, 1H, J19,29= 4.3 Hz, H-19), 4.31 (app.t, 1H,
J29,39= J29,19= 4.7 Hz, H-29), 4.26 (app.t, 1H,
J39,29= J39,49= 5.1 Hz, H-39), 4.26–4.25 (m, 1H, H-49), 4.09–4.04
(m, 1H, H-59a) and 4.00–3.95 (m, 1H, H-59b). 13C (100 MHz,
D2O) d 159.2 (C-6), 156.4 (C-4), 142.1 (C-2), 125.7 (C-5), 110.3
(C-8), 88.1 (C-19), 83.7 (C-49, J= 8.4 Hz), 75.1 (C-29), 69.5 (C-39)
and 62.9 (C-59). 31P (161 MHz, D2O) d 3.8. HRMS (ES
2)
calculated for C10H11IN4O8P 472.9365 (M2H)
2 found 472.9370.
UV (H2O) lmax 261 nm (e 16500).
N1-IMP. To a solution of 8-bromo N1-IMP (3 mmol) and
NaHCO3 (30 mg) in water/EtOH (1:0.5 mL) was added Pd/C
(2 mgs). The mixture was stirred under a hydrogen atmosphere for
5 h after which HPLC analysis showed a new peak at 8.3 mins.
The palladium was removed by filtration and the filtrate was
evaporated leaving a residue which was purified by reverse-phase
column eluted with a gradient of MeCN in 0.05 M TEAB to yield
the desired product as a glassy solid (2.1 mmol, 70%). 1H
(270 MHz, D2O) d 8.57 (s, 1H, H-2), 7.86 (s, 1H, H-8), 6.32 (d,
1H, J19,29= 4.2 Hz, H-19), 4.45 (dd, 1H, J29,39= 5.0 and
J29,19= 4.2 Hz, H-29), 4.42 (app.t, 1H, J39,29= J39,49= 5.0 Hz, H-
39), 4.30–4.27 (m, 1H, H-49) and 4.09–3.97 (m, 2H, H-59). 13C
(100 MHz, D2O) d 154.9 (C-6), 151.1 (C-2), 142.2 (C-8), 88.3 (C-
19), 83.7 (d, J= 8.8 Hz, C-49), 75.2 (C-29), 69.7 (C-39) and 63.0 (C-
59). 31P (161 MHz, D2O) d 0.9. HRMS (ES
2) calcd for
C10H12N4O8P 347.0398 [(M2H)
2] found 347.0396. UV (H2O)
lmax 262 nm (e 12500).
8-Amino N1-IMP. A solution of 8-azido N1-cIDPR [29]
(5 mmol) in 0.2 M HCl (pH 1, made up in D2O) was stirred at
60uC. After 24 hours, 31P NMR showed disappearance of the
pyrophosphate signal around d -10 ppm and formation of two
peaks between 0 and 1 ppm, characteristic of monophosphates.
The reaction mixture was cooled to room temperature, neutral-
ized by addition of 0.1 M NaOH and product purified on a C18
semi-preparative column eluted with a gradient of MeCN in
0.1 M TEAB. The appropriate fractions were collected, evapo-
rated and the residue was dissolved in 0.05 M TEAB to which was
added dithiothreitol (10 mgs). The reaction mixture was stirred at
room temperature in the dark for 3 h, after which HPLC analysis
showed the reaction was complete. The solvent was removed and
the residue applied to a C18 semi-preparative column eluted with
a gradient of MeCN in 0.1 M TEAB to afford the desired
monophosphate (1.1 mmol, 22% over 2 steps). 1H (500 MHz,
D2O) d 8.49 (s, 1H, H-2), 6.32 (brs, 1H, H-19), 4.33–4.36 (m, 2H,
H-29 and H-39), 4.25 (brs, 1H, H-49) and 4.05–4.14 (m, 2H, H-59).
13C (125 MHz, D2O) d 161.4 (C-6), 155.7 (C-4), 152.8 (C-5),
143.6 (C-2), 112.3 (C-8), 89.0 (C-19), 83.1 (d, J= 8.9 Hz, C-49),
75.0 (C-29), 69.0 (C-39) and 63.4 (d, J= 4.5 Hz, C-59). 31P
(202 MHz, D2O) d 0.3. HRMS (ES
2) calcd for C10H13N5O8P
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362.0507 (M2H)2 found 362.0509. UV (H2O) lmax 265 nm (e
11000).
Protein production, crystallization, complex formation
and data collection. Expression, purification, and crystalliza-
tion of wild-type CD38 protein were performed using procedures
as previously described [22]. The CD38/8-amino N1-cIDPR
complex was obtained by incubating pre-formed wild-type CD38
crystals with 30 mM 8-amino N1-cIDPR for 1–2 min at 4uC in
soaking solution (10% PEG 4000, 100 mM MES, pH 6.0, and
30% glycerol). The CD38/cADPcR complex was obtained by
incubating pre-formed CD38 crystals in 33 mM cADPcR for
100 min at 4uC in soaking solution (10% PEG 4000, 100 mM
MES, pH 6.0, and 30% glycerol). X-ray diffraction data were
collected at the Cornell High-Energy Synchrotron Source
(CHESS) A1 station under the protection of a liquid nitrogen
cryo-stream at 100 K. Diffraction images were integrated, scaled,
and merged by using the program HKL2000 [39]. Data reduction
statistics are listed in Table S1.
Structure Refinement
Structures were refined by REFMAC [40] and PHENIX [41]
with the starting model derived from the CD38/N1-cIDPR
complex (PDB code: 2PGJ) [30]. There are two CD38 molecules
in the crystallographic asymmetric unit. The 8-amino N1-cIDPR
and cADPcR molecules were built in O [42] based on the
structure of N1-cIDPR and the sA weighted Fo-Fc difference
electron densities. Solvents were added automatically by ARP/
wARP [43] and manually inspected/modified under the program
O. At the end of refinements, TLS refinement implemented in
PHENIX was introduced to model the data anisotropy. Refine-
ment statistics are also listed in Table S1.
Structural Data
The atomic coordinates and structure factors of CD38/8-amino
N1-cIDPR and CD38/cADPcR have been deposited with the
Protein Data Bank (www.pdb.org) with the accession codes 3U4H
and 3U4I, respectively.
Enzymatic Assay for cADPR Hydrolysis
The inhibition of cADPR hydrolysis by various concentrations
of inhibitor (0–1 mM) was determined by incubating 1 mM
cADPR with 2 mg/mL of CD38 for 10 min at 20–24uC in
25 mM sodium acetate, pH 4.5. The reaction was stopped by the
addition of 150 mM HCl. The precipitated protein was filtered,
and the pH was neutralized with Tris base. After diluting the
mixture 20-fold, the concentration of the unhydrolyzed cADPR
present in the diluted reaction mixture was assayed by the
fluorimetric cycling assay as previously described [44].
Enzymatic Assay for NAD+ Hydrolase Activity
The inhibition of CD38 NAD+ glycohydrolase activity by 8-
NH2-cIDPR (0–1 mM) was determined by incubating 1 mM
NAD+ with 0.1 mg/mL CD38 for 1 min at 20–24uC in 25 mM
sodium acetate pH 4.5. The reaction was stopped by addition of
150 mM HCl, filtered and assayed for NAD+ by the fluorimetric
cycling assay as previously described [44].
Results and Discussion
Molecular Modeling to Predict Structural Modifications
We previously reported the crystal structure of N1-cIDPR with
wild-type CD38 (PDB code 2PGL) [30]. To compare the binding
mode of N1-cIDPR and its analogues with CD38, they were
docked in a similar manner into 2PGL with N1-cIDPR removed
using the flexible docking program GOLD [32–35]. When N1-
cIDPR is redocked back into the vacant active site with the
structural water molecules present, its pose is almost identical to
the position of the ligand in the original protein crystal structure,
providing confidence that docking could be predictive for other
ligands using this model (Figure 3A). The surface view of the active
site complexed with the ligand reveals a small pocket around the 8-
position of the purine ring and a second much larger pocket of
vacant space around the ‘‘southern’’ ribose which could be
exploited to design potential inhibitors of CD38 (Figure 3B).
The stability of N1-cIDPR towards chemical hydrolysis was
recently exploited to generate a series of analogues from the
synthetically versatile parent compound 8-bromo N1-cIDPR [29].
Docking was used to determine the likely binding mode and ligand
contacts arising from substitution of the bromine of 8-bromo N1-
cIDPR by -NH2 at C-8 of the purine ring. The main interactions
predicted for the cyclic backbone are with amino acids Trp-125,
Ser-126, Arg-127, Thr-221 and Phe-222 (binding motif) as well as
Glu-146 (regulatory motif) and Glu-226 (catalytic residue). These
interactions are also observed in the 2PGL crystal structure with
N1-cIDPR co-crystallized. The importance of many of these
residues is highlighted by the fact that they are evolutionarily
conserved – see Figure S4 for an alignment of CD38 from seven
species. The distance between the hydrogen of the amino group of
8-amino N1-cIDPR and the carboxylate oxygen of Asp-155 is 2.63
A˚, which suggests that hydrogen bonding in this area is possible
(Figure 4A and B). It was thus envisaged that the presence of an
amino group might increase affinity of 8-amino N1-cIDPR for the
active site relative to N1-cIDPR with resulting enhanced inhibitory
activity towards CD38. A second ligand, 8-(4-aminobutane) amino
N1-cIDPR, was designed to explore the possibility of a yet stronger
ionic interaction with Asp-155. It was envisaged that a
diaminobutane group at this position might afford a stronger
overall interaction between the ligand and protein, as the primary
amine at the chain terminus could interact through hydrogen
bonding to Thr-158 in addition to a hydrogen bond between the
C-8 amino group and Asp-155, as already predicted by the 8-
amino N1-cIDPR/CD38 docking. The -NH(CH2)4NH2 substitu-
ent could be incorporated during binding in two modes,
depending on the orientation of the -NH hydrogen. The model
was therefore built in the conformation likely to form the most
hydrogen bonds with CD38. The docked distance between the
hydrogen of the secondary amino group and the carboxylate
oxygen of Asp-155 was 2.40 A˚; while the NH2-CO2- distance
between the primary amino group and Thr-158 was 2.11 A˚,
indicating that two hydrogen bonds can in principle be derived
from the C-8 (aminobutyl)amino side chain (Figure 4C).
Synthesis and Characterization of 8-(4-
aminobutane)Amino N1-cIDPR
Few cADPR analogues bearing an extended amino chain at C-8
have been synthesized, presumably due to the instability of
cADPR itself towards hydrolysis. The first, 8-(6-aminohexyl)amino
cADPR, was prepared by direct incubation with Aplysia cyclase of
the commercially available 8-(6-aminohexyl)amino NAD+ [5]. In
contrast, our route depends upon the excellent stability of the N1-
cIDPR template, on which we have previously demonstrated
efficient displacement of the 8-bromo atom [29]. A large excess of
diaminobutane is required to displace the bromine and drive the
reaction to completion over a 10-day period (Figure 5), charac-
terized by a shift in UV absorption from 255 to 265 nm. The
identity of the expected 8-(4-aminobutane)amino N1-cIDPR was
confirmed by spectroscopy. Mass spectroscopy gives a peak with
m/z value of 629.1 (MH)+ consistent with the expected product.
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The 1H NMR spectrum is also in agreement with the proposed
cyclic structure with one broad singlet at 5.93 and a doublet at
5.81 for anomeric protons H-10 and H-19 respectively. In addition,
multiplets at 3.4, 2.1 and 1.6 ppm indicate the presence of the
alkyl chain. Using microwave technology the yield of the
displacement reaction could be improved from 52% to quantita-
tive. Moreover, the reaction could be carried out in 1 h as opposed
to 10 days using the unassisted route. In addition to its application
as a CD38 inhibitor in this study, we anticipate that this
compound should provide an ideal starting point from which an
affinity chromatography column for isolation of cADPR-binding
proteins could be derived.
Synthesis of N1-inosine 59-monophosphate Analogues
While studying the stability of 8-bromo N1-cIDPR it was found
that, on prolonged heating at acidic pH, it degraded very cleanly
to generate a novel class of nucleotide where the N9 glycosidic
bond in the cyclic compound was cleaved in preference to the N1
bond; leaving 8-bromo N1-IMP (Figure 6) [38]. Similar treatment
of 8-iodo N1-cIDPR afforded 8-iodo N1-IMP. Subsequent
palladium catalyzed hydrogenation of 8-bromo N1-IMP afforded
the parent compound N1-IMP. However, 8-amino N1-cIDPR
could not be degraded in the same manner as 8-bromo N1-cIDPR,
presumably due to the free amino group. It required heating for a
longer period at acidic pH which, over time, ended up degrading
the product fully to a complex mixture of compounds. An
alternative method to obtain the fragment is to degrade the parent
8-bromo N1-cIDPR followed by treatment with NaN3 to produce
the 8-azido IMP which in turn could be reduced to the amino
compound. To our surprise, the nucleophilic displacement step by
NaN3 proved unsuccessful. Various changes in the reaction
conditions; converting the starting material from the triethylam-
monium salt to the free acid, or varying the reaction temperature
(80 to 120uC) were fruitless. When treating both 8-bromo N1-
cIDPR and 8-bromo N1-IMP in parallel under identical condi-
tions, only 8-bromo N1-cIDPR was converted to the desired azido
product, therefore ruling out potential chemical contamination.
Given that the only difference between the two starting materials is
the N9 position (which is not alkylated in 8-bromo N1-IMP), we
speculated that in this particular case the C-8 position is not
electrophilic enough to allow the azide to attack and displace the
bromine atom. Instead, the precursor 8-azido N1-cIDPR [29] was
degraded under acidic conditions to prepare 8-azido N1-IMP
which, upon treatment with dithiothreitol, gave the desired 8-
amino N1-IMP. Although we realize this is not an elegant or cost-
effective way of preparing these fragments, a direct synthetic
approach is underway and will be reported in due course.
Figure 3. N1-cIDPR in the CD38 binding site. (A) Comparison between the docked model of N1-cIDPR (carbons in cyan) and the crystal binding
model (carbons in green). The color scheme is O, red; N, dark blue and P, orange and (B) surface view of the active site pocket of the crystal structure
of CD38 with N1-cIDPR bound inside.
doi:10.1371/journal.pone.0066247.g003
Figure 4. Highest scoring docked conformation of N1-cIDPR (A), 8-amino N1-cIDPR (B) and 8-(4-aminobutane)amino N1-cIDPR (C).
The ligands are shown as sticks and the residues as lines. Color codes of the atoms of the ligand are C, cyan, O, red; N, dark blue and P, orange.
Dashed black lines show the hydrogen bond interactions between the ligands and the enzyme. Hydrogen atoms are not shown for clarity.
doi:10.1371/journal.pone.0066247.g004
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Structure of 8-amino N1-cIDPR Complexed with Wild-
type CD38
Preformed crystals of wild-type CD38 were soaked with a
solution of 8-amino N1-cIDPR. Crystals usable for data collection
were obtained and examined by X-ray crystallography to
determine the structure of the enzymatic domain of the CD38/
ligand complex. The structure was refined to a resolution of 1.87A˚
and contained two molecules of CD38 in the asymmetric unit with
8-amino N1-cIDPR present in the respective active sites
(Figure 7A). The 20- and 30-OH groups on the ‘‘northern’’ ribose
form two hydrogen bonds with the carboxylate group of Glu-226.
In addition to Glu-226, the pyrophosphate group interacts with a
number of previously identified amino acids including Trp-125,
Arg-127, Thr-221 and Phe-222 [27]. Importantly, the 8-amino
group forms a hydrogen bond with the carboxylate group of Asp-
155 as predicted by our modeling studies (Figure 7B).
Structure of cADPcR Complexed with Wild-type CD38
Cyclic ADP-carbocyclic ribose was synthesized as a stable
mimic of cADPR in which the oxygen of the ‘‘northern’’ ribose is
replaced by a methylene group [37]. This small change, by
removing the ability to form an oxocarbenium ion in the
‘‘northern’’ ribose, confers stability towards chemical and
biochemical hydrolysis in a different fashion to that afforded by
N1-cIDPR, and cADPcR has also proved to be a potent Ca2+
release agent in sea urchin egg homogenate. Moreover, unlike
cIDPR, cADPcR retains the N6-amino group of cADPR. As with
8-amino N1-cIDPR, preformed crystals of CD38 were soaked in a
solution of cADPcR at pH 6 to form the complex. The structure of
the CD38/cADPcR complex obtained was refined to 2.1 A˚
resolution. As already seen for N1-cIDPR or N7-cGDPR [27],
[30], cADPcR can be detected in only one of the two
crystallographic asymmetric units. Like N1-cIDPR, cADPcR can
reach the catalytic residue Glu-226 and form two hydrogen bonds
with it through the two hydroxyl groups of the carbocyclic ribose.
The diphosphate group is stabilized through a number of H-bonds
with residues Trp-125, Arg-127, Thr-221 and Phe-222 (Figure 8A).
The adenine ring of cADPcR interacts with Glu-146 through a
hydrogen bond with the N6 nitrogen and with Trp-189 through
hydrophobic interaction. As expected, Asp-155 does not appear to
be directly involved in the stabilization of the cADPcR/CD38
complex.
N1-cIDPR was thus the first analogue that could reveal the
likely cADPR binding mode in the wild-type enzyme, but misses
the N6-amino group. It is pleasing now to see with cADPcR that
an analogue that preserves this key cADPR motif still binds
essentially in the same location.
Attempt to Obtain Structural Complexes of 8-bromo N1-
cIDPR and 8-(4-aminobutane)Amino N1-cIDPR with Wild-
type CD38
The co-crystal structure of 8-amino N1-cIDPR bound to wild-
type CD38 encouraged us to attempt crystallization with other
analogues which had been modified in the 8-position. However,
soaking 8-(4-aminobutane) amino N1-cIDPR ligand with CD38
crystals resulted in no electron density in the active site, despite our
prediction that the protonated amine may pair with Asp-155 and
Thr-158. We suggest that this motif may also generally disturb the
architecture of the protein too much as the ligand seeks out other
potential ionic charged partners. A similar problem was encoun-
tered in attempts to isolate a productive complex with 8-bromo
N1-cIDPR, suggesting either weaker binding for this ligand, or
even possibly, cleavage by the protein. However, the latter seems
unlikely, as incubation of 8-bromo N1-cIDPR with CD38 revealed
no change in the nucleotide profile when analyzed by HPLC after
18 h (data not shown). Similar stability was observed by
Kirchberger et al. when studying the metabolic stability of N1-
cIDPR derivatives [45]. Despite this, we note vide infra that 8-
bromo N1-cIDPR does bind with an IC50 actually better than N1-
cIDPR, but that the diaminobutane derivative binds very poorly.
Figure 5. Preparation of 8-(4-aminobutane)amino N1-cIDPR. Reagents and conditions: i) diaminobutane, MilliQ, rt, 10 days or diaminobutane,
MilliQ, microwave, 70uC, 1 h.
doi:10.1371/journal.pone.0066247.g005
Figure 6. Preparation of N1-IMP compounds. Reagents and conditions: i) 0.2 M HCl, 60uC, 24 h; ii) Pd/C, H2, NaHCO3, MilliQ-EtOH, 5 h; iii)
dithiothreitol, 0.05 M TEAB, 3 h.
doi:10.1371/journal.pone.0066247.g006
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Inhibition of Wild-type CD38-catalyzed cADPR Hydrolysis
by N1-cIDPR Analogues
N1-cIDPR binds in the active site of wild-type CD38, therefore
blocking entry and subsequent hydrolysis of cADPR, with an IC50
of 276 mM. Our modeling studies, as well as the X-ray data
obtained for 8-amino N1-cIDPR and cADPcR, suggest that the
active site of CD38 has good affinity for both classes of non-
hydrolyzable cADPR analogue; and that they should block entry
of cADPR into the catalytic pocket. The inhibition of CD38-
catalyzed cADPR hydrolysis was thus measured for all cyclic
analogues explored in this study (Figure 9).
The higher definition of the X-ray maps for the 8-amino N1-
cIDPR/CD38 complex, in addition to the extra hydrogen bond
between the amino group and the carboxylate of Asp-155, indicate
a likely increase in affinity of this ligand for the protein over the
parent N1-cIDPR. Indeed, 8-amino N1-cIDPR inhibited cADPR
hydrolysis with an IC50 of 56 mM, over 5 times better than that
obtained for N1-cIDPR (Table 1). The crystal structures of N1-
cIDPR and 8-amino N1-cIDPR in complex with CD38 were
Figure 7. The crystal structure of CD38 with 8-amino N1-cIDPR. (A) View of the overall structure of the CD38/8-amino N1-cIDPR complex
showing a ligand present in each molecule of CD38. (B) Structure of 8-amino N1-cIDPR complexed with wild-type CD38. The sA weighted different
electron density is shown as gray isomesh contoured at 2.5s. H-bonds are shown as dashed lines and colored in cyan.
doi:10.1371/journal.pone.0066247.g007
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Figure 8. The crystal structure of CD38 with cADPcR. (A) Structure of cADPcR complexed with wild-type CD38. The sA weighted Fo-Fc
different electron density is shown as gray isomesh contoured at 2.5s. H bonds are shown as dashed lines and colored in cyan (B) Binding
comparison between N1-cIDPR (carbons in green) and cADPcR (carbons in cyan) complexed with CD38, showing overlap of their ‘‘northern’’ ribosyl
phosphate motifs.
doi:10.1371/journal.pone.0066247.g008
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aligned based on their active site residues. Both structures are very
similar except for the position of Glu-146. In the 8-amino N1-
cIDPR complex, the side chain of Glu-146 is displaced signifi-
cantly to form an H-bond with the N7 atom of the hypoxanthine
ring (Figure 10; such movement of Glu-146 could not have been
readily predicted from the non-dynamic docking protocol used in
our modeling studies). The conformational change of Glu-146
probably reflects the enhanced affinity between the inhibitor and
CD38. The high resolution crystal structure of cADPcR bound in
the active site illustrates two hydrogen bonds with Glu-226
(Figure 8). Furthermore, the presence of the N6 atom (as in
cADPR) favors hydrogen bonding to Glu-146, which may explain
the improved affinity of cADPcR for CD38, compared to N1-
cIDPR, resulting in improved inhibition of cADPR hydrolysis
(IC50 = 129 mM vs 276 mM).
8-(4-Aminobutane)amino N1-cIDPR is the poorest inhibitor of
cADPR hydrolysis with an IC50 of approximately 2 mM
(estimated by projection). As shown in Figure 3B, there is only a
small pocket around the 8 position of the purine ring and it might
be that this space is too tight to accommodate the diaminobutane
chain. Indeed, as shown in Figure 4C, the diaminobutane group
appears to protrude from the active site.
Our docking studies indicate that 8-bromo N1-cIDPR should fit
in the active site of CD38 in a similar manner to 8-amino N1-
cIDPR (data not shown). Since the bromo and amino groups are
of similar size, it may be that they both sit well in the pocket
around the C-8 position and therefore provide a better fit in the
active site than N1-cIDPR itself. This may explain the improved
IC50 of 8-bromo N1-cIDPR towards cADPR hydrolysis by CD38
(158 mM) relative to N1-cIDPR.
Based on these results, a very preliminary SAR can be
constructed (Figure 11). The oxo group at the 6-position of the
purine ring appears to be useful for inhibitory activity, primarily
due to conferring resistance to CD38-catalyzed hydrolysis. When
the oxo group is replaced by an imino group (as in cADPR, the
parent compound), inhibition is improved providing the nucleo-
tide is non-hydrolyzable as in cADPcR where the ‘‘northern’’
ribose is replaced by a carbocycle. This is perhaps unsurprising
since the imino group can form a hydrogen bond with Glu-146.
There is a small pocket around the 8-position of the purine ring
and groups at this position appear to be crucial for improved
inhibitory activity. An amino group, as predicted by modeling and
confirmed by crystallography, seems ideal as it is small enough to
fit in the pocket and forms a new hydrogen bond with Asp-155.
Inhibition of NADase Activity of Wild-type CD38
The majority of published studies regarding CD38 inhibition
have focused on the ability of compounds to inhibit the NADase
activity of CD38, rather than its cADPR hydrolase activity. In
order to compare our inhibitors, we therefore tested 8-NH2-N1-
cIDPR (our best cyclic inhibitor with a cADPR hydrolase IC50 of
56 mM) as an inhibitor of NADase activity, and found it to have an
IC50 of 21 mM (Figure S1). This places it among the more potent
inhibitors in this class. Furthermore, it suggests that the
compounds in this study may have wider application as general
CD38 inhibitors and that, in this case, they do not demonstrate
specificity for the cADPR hydrolase activity of CD38, despite their
similarity in structure to cADPR.
N1-Inosine 59-monophosphate Fragments as Inhibitors of
cADPR Hydrolysis
A binding comparison between N1-cIDPR and cADPcR
complexed with wild-type CD38 shows that both ligands bind to
the active site in a similar position and orientation. Indeed, the
‘‘northern’’ ribose monophosphate of N1-cIDPR and the carbo-
cyclic ribose monophosphate of cADPcR overlap whilst the rest of
the molecule is accommodated in a potentially more flexible
fashion across the open face of the pocket (Figure 8B). This
suggests that the ‘‘northern’’ ribose part of the cyclic dinucleotide
(ribose and/or carbocycle) is more important in binding than the
‘‘southern’’ part. To further investigate this hypothesis, we tested
our small series of N1-inosine 59-monophosphate (N1-IMP or,
more strictly, N1-hypoxanthine ribose 59-monophosphate - note
that these compounds correspond formally to the N1-inosine 599-
Figure 9. Inhibition of cADPR hydrolysis by synthetic inhibitors. CD38 hydrolysis activity plotted against analogue concentration.
doi:10.1371/journal.pone.0066247.g009
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monophosphate fragment when using the cyclic nucleotide
notation adopted herein) fragments as inhibitors of CD38-
catalyzed cADPR hydrolysis (Figure 12). 8-Bromo N1-IMP
showed an IC50 of 201 mM which is consistent with what was
observed for the cyclic compound (Table 1). In contrast, 8-iodo
N1-IMP had a much higher IC50 (estimated around 1.24 mM by
projection). This may suggest that, similar to the 8-diaminobutane
chain, the 8-iodo substituent is too large to fit comfortably into the
binding site pocket. Surprisingly, the parent N1-IMP was nearly 20
fold better than its cyclic counterpart with an IC50 of 14 mM (cf.
N1-cIDPR 276 mM). This was unexpected; for the series of cyclic
compounds an opposite trend was observed in which exploiting
the binding pocket (for example with the 8-bromo substituent) led
to better inhibition of cADPR hydrolysis. The 8-amino N1-IMP
was also an order of magnitude better than its cyclic counterpart
(7.6 mM cf. 8-NH2-N1-cIDPR at 56 mM), making this the most
potent inhibitor of cADPR hydrolase activity developed in this
study. In this case, we suspect that this may be attributed to the re-
introduction of the hydrogen bond to Asp-155.
To further investigate the binding of the N1-IMP fragments, we
docked the four ligands into two crystal structures of CD38; the
2PGJ structure with N1-cIDPR as ligand, and the 3U4H structure
reported here with 8-NH2-cIDPR as the ligand. When docked into
the 2PGJ structure, all four N1-IMP ligands resulted in almost
identical docked poses (exemplified by 8-amino N1-IMP, Figure
S2). This docking suggests that the N1-IMP ligands do not
penetrate as far into the binding site as N1-cIDPR, and that the
hydrogen bonds from the 29- and 39-OH on the ribose to the
catalytic acid, Glu-226, do not form. The phosphate attached to
the N1-IMP ribose appears to overlay the crystal structure
‘‘southern’’ ribose phosphate. It may be that the formation of a
hydrogen bond between the side chain of Arg-127 and the N1-
IMP phosphate prevents further penetration of the ligand into the
binding site. A key change in the binding of the docked N1-IMP
ligands is that the hypoxanthine ring binds upside down compared
to the crystal structure ligand (N1-cIDPR), with the 6 = O pointing
down into the binding site, and the N3 and N9 pointing towards
the protein. As previously discussed, when CD38 binds cADPR,
the 6-amino substituent forms a hydrogen bond to Glu-146. When
N1-cIDPR binds to CD38, this hydrogen bond cannot form: there
may even be some repulsion between the oxygen lone pairs.
Unlike in the cyclic N1-cIDPR ligand, the N1-IMP ligands have
flexibility around the N1-ribose bond, allowing the hypoxanthine
Figure 10. Superimposition of the CD38/N1-cIDPR complex (shown in yellow sticks) with the CD38/8-amino N1-cIDPR.
doi:10.1371/journal.pone.0066247.g010
Table 1. Inhibition of cADPR hydrolysis by CD38 for cIDPR
and N1-IMP analogue.
Compound IC50
cIDPR analogues
8-Amino N1-cIDPR 56 mM 69 mM
cADPcR 129 mM 612 mM
8-Bromo N1-cIDPR 158 mM 613 mM
N1-cIDPR 276 mM 610 mM [30]
8-(4-Aminobutane) .1 mM
amino N1-cIDPR
N1-IMP analogues
8-Iodo N1-IMP .1 mM
8-Bromo N1-IMP 201 mM 641 mM
N1-IMP 14 mM 65 mM
8-Amino N1-IMP 7.7 mM 60.2 mM
doi:10.1371/journal.pone.0066247.t001
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ring to dock in the most energetically favorable way. The docking
into the 2PGJ crystal structure did not allow us to explain the
observed differences in binding upon 8-substitution of the N1-IMP
ligands.
However, when the four ligands were docked into the 3U4H
structure, strikingly different poses were adopted by the ligands
depending on their 8-substituents. The 8-bromo and 8-iodo N1-
IMP dock in identical poses which are considerably further out of
the binding pocket than the crystallized cyclic compound
(Figure 13A). The hypoxanthine ring again docks upside down,
with the 6 = O pointing into the binding pocket. Energy
minimization of this pose gave identical results for both ligands,
pushing the hypoxanthine ring further away from the binding
pocket. A shift in the protein structure around the catalytic residue
Glu-226 was also observed on minimization, to regenerate the
hydrogen bonds to the 29- and 39-hydroxyls. The distance of the
hypoxanthine ring from the protein precludes any interactions
(e.g. between N3 or N9 and Glu-146) and may explain the poor
inhibition of cADPR hydrolysis observed for these two analogues.
In contrast, docking the 8-NH2-N1-IMP ligand into the 3U4H
crystal structure gave two contrasting top-ranked results
(Figures 13B and C). The same two results were observed upon
docking of the N1-IMP ligand. In the first pose (Figure 13B), the
hypoxanthine ring docks upside down, compared to the cyclic
ligand. However with the 8-H or 8-NH2 substituents, the
hypoxanthine ring overlays the crystal structure ligand very well,
suggesting that these two 8-substituents are able to better access
the binding pocket. In the second observed pose (Figure 13C), the
hypoxanthine ring, ‘‘northern’’ ribose and phosphate all dock in
an almost exact overlay of the crystal structure cyclic ligand.
Energy minimization of both the docked poses showed minor
movement further into the binding pocket, to optimize the
interaction between the 29- and 39-hydroxyls and Glu-226, and
between the phosphate and Ser-126. In both energy minimized
poses, the 8-NH2 group is able to form a hydrogen bond with Asp-
155. Taken together, these docked poses indicate a much better
affinity of the N1-IMP and 8-NH2-N1-IMP ligands for the binding
site, which agrees with the results observed in the inhibition assay.
This idea was further supported by the results of minimizing the
8-amino N1-IMP fragment in situ, in both crystal structures (S3).
The hydrogen bonds from the 29- and 39-OH to the catalytic acid,
Glu-226, are preserved as is the hydrogen bond between the
Figure 11. Preliminary structure-activity relationship for inhibitors of cADPR hydrolysis by CD38.
doi:10.1371/journal.pone.0066247.g011
Figure 12. Inhibition of cADPR hydrolysis by N1-IMP fragments.
doi:10.1371/journal.pone.0066247.g012
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phosphate and side chain of Ser-126. The ribose and the 59-
phosphate of the N1-IMP fragment and the ‘‘northern’’ ribose and
50-phosphate of either 8-NH2-cIDPR or N1-cIDPR lie in almost
identical positions. Without the restraint of the macrocycle, the
hypoxanthine ring is tilted away from the protein compared to the
crystal structure ligand, with the carbonyl oriented away from the
oxygens of Glu-146 - this effect is much more pronounced in the
2PGJ crystal structure where N1-cIDPR was the original ligand.
This tilting may reduce any lone-pair repulsion.
The molecular docking and minimization suggest that the N1-
IMP fragments, not surprisingly, have flexibility by rotation of the
hypoxanthine ring to adopt a better orientation to optimize the
interactions between the ligand and the protein for favorable
binding. This explains the more efficient binding seen for 8-NH2-
N1-IMP and N1-IMP, compared to their cyclic counterparts.
Furthermore, the increase in binding seen for 8-NH2-N1-IMP can
be attributed to the formation of the hydrogen bond from the 8-
amino substituent to the side chain of Asp155, seen in the energy
minimized pose and also observed for 8-NH2-cIDPR.
In summary, inhibition of CD38-catalyzed cADPR hydrolysis
represents an important approach to the search for agents for
intervention in CD38-related diseases, yet this is a relatively
unexplored area and there is a need to identify lead structures.
Crystallographic studies have identified key residues critical in
regulating the multiple functions of the enzyme as well as its
catalytic activity. N1-cIDPR is the first non-hydrolyzable analogue
of cADPR to be crystallized with wild-type CD38; it inhibits
cADPR hydrolysis and provides an excellent starting template for
structure-based design. Aided by molecular modeling, N1-cIDPR
was functionalized at the C-8 position of the purine ring. High
resolution crystallography and IC50 measurements were used to
identify 8-amino N1-cIDPR as the best cyclic inhibitor of the small
series studied, including the unrelated cADPcR with an intact N6-
amino group. This is thus the first such inhibitor of CD38-
catalyzed cADPR hydrolysis evolved using structure-based con-
siderations, and these data suggest the importance of hydrogen
bonding interactions both at the C-8 position and via movement of
Glu-146 for affinity refinement. Both cADPcR and 8-amino N1-
cIDPR can reach the catalytic Glu-226 in the active site,
mimicking most likely the actual location of cADPR during
catalysis and demonstrating the power of our approach to use a
structurally engineered non-hydrolyzable analogue with the native
enzyme, as opposed to the alternative co-crystallization of cADPR
with a mutant enzyme, that was earlier shown to generate a
different binding mode. Comparative examination of the crystal
structures obtained with cyclic analogues suggested that the 20-
and 30-hydroxyls and the 50-monophosphate group are crucial in
the inhibition of cADPR hydrolysis, whilst the ‘‘southern’’ ribose
monophosphate is apparently not important. This was tested and
confirmed using the N1-IMP fragments. The lower molecular
weight and reduced complexity of these compounds makes them
attractive as a starting point for further inhibitor design. The most
active inhibitor, 8-NH2-N1-IMP, is among the best reported non
covalent inhibitors of CD38 activity thus far. Further development
of these substantially simplified non-cyclic compounds should
enable the design of simple, high affinity CD38 inhibitors for
pharmacological intervention.
Supporting Information
Figure S1 NADase activity of 8-NH2-N1-cIDPR.
(TIF)
Figure S2 Docked pose of 8-NH2-N1-IMP in the 2PGJ
crystal structure. The crystal structure ligand is shown in cyan,
and the docked ligand in pink. All four N1-IMP ligands docked in
an almost identical fashion.
(TIF)
Figure S3 Energy minimized pose of 8-NH2-N1-IMP. (A)
The 3UH4 crystal structure with 8-Amino cIDPR (protein –
green; ligand – cyan). The ligand had atoms deleted to generate 8-
Amino N1-IMP. This protein-ligand complex was put through
1,000 rounds of energy minimization to leave the purple protein
and yellow ligand. There is very little difference in the structures.
The same hydrogen bonds between the protein and the ligand are
formed. (B) Energy minimized pose of 8-amino N1-IMP in the
2PGJ CD38 crystal structure; Crystal structure protein is shown in
green, and the cIDPR ligand in cyan. The minimized protein is
shown in purple, and the minimized ligand in yellow.
(TIF)
Figure S4 Sequence alignment of CD38 from seven
species. Residues identical to those in the human protein are
highlighted in yellow. Residues mentioned in the text are shown in
blue: several of these residues are shown in Figure 11. Human –
Homo sapiens, UniProtKB ID P28907. Chimp – Pan troglodytes,
H2QP89. Monkey – Macaca fascicularis, Q5VAN0. Mouse – Mus
musculus, P56528. Rat – Rattus norvegicus, Q64244. Rabbit –
Oryctolagus cuniculus, Q9MZ03. Cow – Bos taurus, Q9TTF5. The
sequence alignment was performed by MultAlin, http://multalin.
toulouse.inra.fr/multalin/multalin.html.
(TIF)
Table S1 Crystallographic data and refinement statis-
tics.
(TIF)
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